Literature DB >> 9154975

Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method.

D K Jones-Hertzog1, W L Jorgensen.   

Abstract

The binding of sulfonamide inhibitors to human thrombin is examined to evaluate the viability of calculating free energies of binding, deltaGb, utilizing Monte Carlo (MC) statistical mechanics with a linear response approach. Coulombic and van der Waals energy components determined from MC simulations of the bound and unbound inhibitors solvated in water plus a solvent-accessible surface area term, as an index for cavity formation, were correlated with the free energies of binding for the inhibitor MD-805 and six derivatives. The best correlations yield an average error of 0.8 kcal/mol for the seven binding affinities, which cover an observed range of 6.0 kcal/mol. The MC simulations also provided insights into the interactions occurring in the active site and the origins of variations in deltaGb. Equatorial placement of the carboxylate group at C2 in the piperidine ring of the inhibitors causes electrostatic destabilization with the side chain of Glu-H192, while axial disposition of the C4-methyl group reduces favorable hydrophobic interactions in the P-pocket of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154975     DOI: 10.1021/jm960684e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  Calculations of free-energy contributions to protein-RNA complex stabilization.

Authors:  M A Olson
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

2.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors.

Authors:  V Zoete; O Michielin; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

3.  A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.

Authors:  Akash Khandelwal; Viera Lukacova; Dogan Comez; Daniel M Kroll; Soumyendu Raha; Stefan Balaz
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

4.  Processing multimode binding situations in simulation-based prediction of ligand-macromolecule affinities.

Authors:  Akash Khandelwal; Viera Lukacova; Daniel M Kroll; Soumyendu Raha; Dogan Comez; Stefan Balaz
Journal:  J Phys Chem A       Date:  2005-07-28       Impact factor: 2.781

5.  Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin.

Authors:  Emilia L Wu; Ye Mei; KeLi Han; John Z H Zhang
Journal:  Biophys J       Date:  2007-03-23       Impact factor: 4.033

Review 6.  Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go.

Authors:  N Moitessier; P Englebienne; D Lee; J Lawandi; C R Corbeil
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

7.  Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands.

Authors:  Stefano Costanzi; Irina G Tikhonova; T Kendall Harden; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2008-05-16       Impact factor: 3.686

8.  Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor.

Authors:  Santiago Vilar; Joel Karpiak; Stefano Costanzi
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

9.  Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases.

Authors:  J Marelius; M Graffner-Nordberg; T Hansson; A Hallberg; J Aqvist
Journal:  J Comput Aided Mol Des       Date:  1998-03       Impact factor: 3.686

10.  Free energy determinants of binding the rRNA substrate and small ligands to ricin A-chain.

Authors:  M A Olson; L Cuff
Journal:  Biophys J       Date:  1999-01       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.